• 1
    Yelin E, Callahan LF, for the National Arthritis Data Work Group. The economic cost and social and psychological impact of musculoskeletal conditions. Arthritis Rheum 1995; 38: 135162.
  • 2
    Callahan LF. Economics of rheumatoid arthritis. Rheumatoid Arthritis 1999; 2: 35.
  • 3
    Kremer JM. Methotrexate and emerging therapies. Rheum Dis Clin North Am 1998; 24: 6518.
  • 4
    Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 81822.
  • 5
    Kobelt G, Eberhardt K, Jönsson L, Jönsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999; 42: 34756.
  • 6
    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 2539.
  • 7
    Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis: the Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995; 333: 13741.
  • 8
    O'Dell JR, Haire C, Erikson N, Drymalski W, Palmer W, Maloley P, et al. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate. J Rheumatol Suppl 1996; 44: 724.
  • 9
    O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334: 128791.
  • 10
    Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 47886.
  • 11
    Anis AH, Tugwell PX, Wells GA, Stewart DG. A cost effectiveness analysis of cyclosporine in rheumatoid arthritis. J Rheumatol 1996; 23: 60916.
  • 12
    Kavanaugh A, Heudebert G, Cush J, Jain R. Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model. Semin Arthritis Rheum 1996; 25: 297307.
  • 13
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 72735.
  • 14
    Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 15
    Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999; 42: 120918.
  • 16
    Wolfe F. The natural history of rheumatoid arthritis. J Rheumatol Suppl 1996; 44: 1322.
  • 17
    Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000; 43: 229.
  • 18
    Felson DT, Anderson JJ, Lange MLM, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998; 41: 156470.
  • 19
    O'Dell JR. Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis. Rheum Dis Clin North Am 1998; 24: 46577.
  • 20
    O'Dell J, Leff R, Paulsen G, Haire C, Mallk J, Eckhoff PJ, et al. Methotrexate(M)-hydroxychloroquine(H)-sulfasalazine(S) versus M-H or M-S for rheumatoid arthritis: results of a double-blind study [abstract]. Arthritis Rheum 1999; 42 Suppl 9: S117.
  • 21
    Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159: 254250.
  • 22
    Moreland LW, Baumgartner SW, Tindall EA, Schiff RM, Fleischmann RM, Weaver AL, et al. Longterm treatment of DMARD failing rheumatoid arthritis patients with TNF receptor p 75 Fc fusion protein (TNFR:Fc; ENBREL) [abstract]. J Invest Med 1998; 46: 229A.
  • 23
    O'Dell J, Paulsen G, Haire C, Palmer W, Wees S, Eckhoff J, et al. Combination DMARD therapy with methotrexate-sulfasalazine-hydroxychloroquine in rheumatoid arthritis: continued efficacy with minimal toxicity at 5 years [abstract]. Arthritis Rheum 1998; 41 Suppl 9: S132.
  • 24
    Medical Economics Company. 1999 red book. Montvale (NJ): Medical Economics; 1999.
  • 25
    Prashker MJ, Meenan RF. The total costs of drug therapy for rheumatoid arthritis: a model based on costs of drug, monitoring, and toxicity. Arthritis Rheum 1995; 38: 31825.
  • 26
    American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39: 72331.
  • 27
    Smith SL. Medicare RBRVS: the physician's guide. Chicago: American Medical Association; 1999.
  • 28
    Haddix AC, Teutsch SM, Shaffer PA, Dunet DO. Prevention effectiveness. New York: Oxford University Press; 1996.
  • 29
    Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol Suppl 1996; 44: 4751.